Kintor Pharmaceutical (09939) Announces October 2025 Monthly Return Showing Unchanged Share Capital
Bulletin Express
Nov 03
For the month ended 31 October 2025, Kintor Pharmaceutical Limited (09939) reported that its authorized share capital remained at 700,000,000 ordinary shares at a par value of US$0.0001 per share, totaling US$70,000. This reflects no change compared to the close of the preceding month.
The company’s issued share capital also remained unchanged at 468,172,600 ordinary shares with zero treasury shares. The latest report indicates no additional issuance of options, warrants, or other convertible securities, and no activities involving other agreements or arrangements to issue shares. The company confirms compliance with relevant listing and regulatory requirements throughout the reporting period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.